Skip to main content

Table 1 Baseline and outcome characteristics of TB patients receiving V5 in combination with TB drugs for 30 days

From: Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

No. Sex Age Months
on ATT
prior
to V5
Dx TB
drugs
regime
Smear
status
Liver size
in cm over
normal
Erythrocyte
sedimentation
rate (mm/h)
Lymphocytes
(%)
Leukocytes
(× 109/L)
Hemoglobin
(g/L)
Body weight
(kg)
Total
bilirubin
(μmol/L)
ALT
(mM/h/ml)
       before after before after before after before after before after before after before after before after before after
1 M 43 0 1stDx HRZE 3 1 2 0 50 30 18 23 11.7 9.2 129 122 64 65 8.8 8.8 0.4 0.1
2 M 39 0 1stDx HRZE 3 1 0 1 17 16 28 25 4.4 5.4 142 139 65 66 9.9 8.8 0.2 0.6
3 M 44 1 1stDx HRZES 1 0 1 0 21 15 19 29 6.1 5.6 127 116 74 78 8.8 9.9 0.6 0.5
4 M 60 3 1stDx HRZES 3 0 1 0 27 20 29 31 6.1 6 144 122 71 74 8.8 8.8 0.7 0.1
5 F 27 1 1stDx HRZES 3 2 1 0 58 40 16 22 11 8 101 110 43 49 8.8 8.8 0.7 0.7
6 M 26 3 1stDx HRZES 3 1 3 1 15 6 30 37 11.6 6 158 140 66 69 8.8 12.1 0.9 1.7
7 M 57 1 1stDx HRZES 2 0 0 0 32 9 21 34 5.3 5.1 109 123 60 63 12.1 9.9 0.1 0.5
8 M 31 0 1stDx HRZES 1 0 0 0 36 26 21 29 7.5 6.6 134 136 62 68 8.8 9.9 0.3 0.4
9 M 39 0 1stDx HRZES 2 1 0 0 50 30 14 17 11.7 9.6 154 144 63 67 8.8 8.8 0.2 0.2
10 M 31 3 1stDx HRZES 3 0 0 0 37 2 33 46 9.7 4 145 151 64 67 9.9 8.8 0.4 0.4
11 M 59 0 1stDx HRZES 1 0 1 1 25 24 27 29 6.6 5.2 138 136 61 66 18.1 12.1 0.3 0.5
12 M 26 0 1stDx HRZES 3 0 3 1 19 9 24 21 5.7 6.0 156 153 70 73 8.8 8.8 1.3 0.7
13 M 51 1 1stDx HRZES 3 0 1 2 15 6 16 29 14.2 6.9 142 150 81 81 12.1 8.8 0.6 0.9
14 F 46 1 RTB HRZES 3 0 0 0 17 3 17 21 8.3 7.7 103 110 52 58 8.8 8.8 0.3 0.1
15 F 54 0 RTB RZEO 3 0 3 1 16 8 24 34 6.1 5.1 143 128 58 59 8.8 8.8 1.2 0.6
16 F 35 1 RTB HRZEA 3 0 0 0 32 15 18 37 6.7 5.5 142 136 62 67 8.8 8.8 0.2 0.2
17 M 49 1 MDR HRZEO 3 0 1 1 55 40 18 37 20.4 7.5 138 100 73 75 12.1 9.9 0.8 0.8
18 M 29 9 MDR HEAOC 3 1 5 3 25 14 11 26 7.9 7.9 129 138 59 62 8.8 8.8 0.5 0.9
19 F 53 2 MDR ZEPAO 0 0 0 0 19 17 35 31 4.4 5.8 139 167 55 59 14.3 10.4 0.3 0.4
20 M 29 0 MDR ZEPAO 2 0 1 0 10 8 33 35 10 6.2 147 148 65 69 8.8 8.8 0.6 0.6
21 M 29 4 MDR ZEPAO 2 0 3 0 25 17 26 37 10.1 6.8 135 133 57 60 9.9 8.8 1.3 0.6
22 M 49 1 MDR ZEPO 1 0 2 0 24 17 12 26 5.3 4.9 159 137 72 74 14.2 9.9 1 0.6
23 M 52 0 MDR ZPAO 1 0 3 1 24 18 24 26 5 4.2 124 128 68 73 13.5 8.8 1.4 0.7
24 M 22 1 MDR CsCiGF 1 0 0 0 23 18 25 27 19.6 7.2 121 131 66 73 8.8 8.8 0.1 0.2
  5/19 Mean
= 40.8
± 12
Median
= 41
Mean = 1.6
± 2.5
Median
= 1
1stDx = 13
RTB = 3
MDR = 8
  1/23
2.2/3
18/6
0.3/0
1.3
± 1.4/1
0.5
± 0.8/0
28 ±
13.4
17 ±
10.4
22.5
± 6.8
29.5
± 6.7
9 ± 4.3 6.4 ± 1.4 135.8
± 15.8
133.3
± 15.5
63.8
± 7.9
67.3
± 7.3
10.4
± 2.5
9.4
± 0.99
0.6
± 0.4
0.54
± 0.35
       P = 0.000027 P = 0.0018 P = 8.3E-007 P = 2.8E-005 P = 0.0024 P = 0.39 P = 2.3E-009 P = 0.03 P = 0.47
  1. TB drugs used in this arm are abbreviated as follows: Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), Streptomycin (S), Ofloxacin (O), Amikacin (A), Capreomycin (C), Para-aminosalicylic acid (P), Cs (Cycloserine), Cilastatin (Ci), Gatifloxacin (G), Metronidazole (F), Prothionamide (Pt)
\